NEW YORK, June 1 (GenomeWeb News) - Berthold Technologies GmbH & Co. KG will distribute Acolyte's BacLite RapiTect range of enumeration assays in Europe and U.S. under a marketing agreement, Acolyte Biomedica said today.
The assay range uses adenylate kinase as a highly sensitive marker of viable cells. The technology, originally developed by the UK Ministry of Defence, is up to 100 times more sensitive than standard ATP bioluminescence and up to one million times more sensitive than optical measurements. Acolyte has exclusive licenses to the technology for commercial exploitation in life sciences research.
Financial details were not disclosed.